Showing results (51-60 of 58) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.Genome Biology|November 5, 2020
Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticityWon-Chul Lee, Alexandre Reuben, Xin Hu, et al.The Lancet. Oncology|October 2, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort studyAlessandro Di Federico, Kaiwen Wang, Monica F Chen, et al.The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.Pageof 6